The Role and Research Progress of Inhibitor of Differentiation 1 in Atherosclerosis

Abstract

Inhibitor of differentiation 1 has a helix-loop-helix (HLH) structure, belongs to a class of molecules known as the HLH trans-acting factor family, and plays an important role in advancing the cell cycle, promoting cell proliferation and inhibiting cell differentiation. Recent studies have confirmed that inhibitor of differentiation 1 plays an important role in the endothelial-mesenchymal transition of vascular endothelial cells, angiogenesis, reendothelialization after injury, and the formation and rupture of atherosclerotic plaques. An in-depth understanding of the role of inhibitor of differentiation 1 in atherosclerosis will provide new ideas and strategies for the treatment of related diseases.

A new hope for targeted therapy of ischemia-reperfusion injury: E2F2, an important transcription factor in H/R process

“…Studies have reported that BMP9-ID1 signaling pathway may activate HIF-1α/VEGFA expression [36] . Consistent with our ndings, ID1 is downregulated during IRI, inhibits cell proliferation and activates the apoptotic pathway, while ID1 is an effector of the p53-dependent DNA damage response pathway and is involved in endothelial cell formation and angiogenesis, which is consistent with E2F2 during IRI [37] . On the other hand, ID1 down-regulation is associated with hypoxia.…”

Histone modification of endothelial-mesenchymal transition in cardiovascular diseases

“…In 2007, it was first discovered in adult organisms that EndMT can promote myocardial fibrosis and participate in the process of pathological tissue remodeling (3). In recent years, researches on EndMT and atherosclerosis (AS), pulmonary hypertension, myocardial fibrosis and other cardiovascular diseases have been carried out continuously, and it has been suggested that EndMT is the main contributor to these diseases (4)(5)(6). Therefore, targeting EndMT may be of great significance in the prevention and treatment of cardiovascular diseases.…”